Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 50mg - tapentadol (tapentadol hydrochloride) 50mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 75mg - tapentadol (tapentadol hydrochloride) 75mg

Canada - English - Health Canada

apotex inc - tapentadol (tapentadol hydrochloride) - tablet (immediate release) - 100mg - tapentadol (tapentadol hydrochloride) 100mg

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - tapentadol tartrate - prolonged-release tablet - tapentadol

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve nucynta tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia nucynta tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.5)] - known or suspected gastrointestinal obstruction, including suspected paralytic ileus [see warnings and precauti